April 10, 2026

A mouse model for Dry Eye Disease

A mouse model for Dry Eye Disease

Experimentica utilizes a validated mouse model of dry eye disease. Dry eye disease-like pathology is induced using transdermal scopolamine patches in combination with desiccating environmental stress. The induced pathology is characterized using corneal fluorescein staining, tear volume measurements, and histology for lacrimal gland infiltration, goblet cell loss, and corneal abnormalities.

Dry eye disease, also referred to as keratoconjunctivitis sicca, dry eye syndrome, and dysfunctional tear syndrome, is a multifactorial ocular surface disease characterized by ocular discomfort, irritation, and visual disturbance. It ranks among the most frequently encountered ocular morbidities, with more than 25% of patients attending ophthalmic clinics reporting these symptoms (Dana et al. 2019).

The global prevalence of dry eye disease is estimated to range from 7% to 34%, depending on diagnostic criteria and the population surveyed (Deo and Nagrale 2024). The steep rise in annual dry eye disease incidence and prevalence over the past decade has recently been estimated (Zhang et al. 2024).

In 2002, Dursun and colleagues published a mouse model of dry eye disease by combining application of transdermal scopolamine patches together with a desiccating environmental stress (Dursun et al. 2002). At Experimentica, we use corneal fluorescein staining (CFS) to confirm successful model induction.

Figure 1. Corneal fluorescein staining of damaged epithelial cell layer.

CFS is scored using the modified Oxford score method by assigning scores from 0 (healthy corneal epithelial cell layer with no observable fluorescein staining) to 4 (severe corneal epithelial cell damage with widespread confluent staining of the cornea.

Figure 2. Corneal fluorescein score at Day 21 of the study follow-up in naïve, untreated and PBS-treated eyes.

In addition, the evaluation of dry eye disease-like pathology can be performed with tear volume measurements and histological assessment of immune cell infiltration in lacrimal glands, quantification of goblet cells in the conjunctiva or corneal thickness and the number of corneal epithelial layers.

Figure 3. H&E staining of lacrimal gland, PAS staining of Goblet cells, and H&E staining of cornea.

Contact us for more information or schedule the meeting with our experts!

Contact usLearn more about our Dry Eye Disease model

References

Our latest News

discover more
How is TR-FRET Used in Drug Discovery?

How is TR-FRET Used in Drug Discovery?

This post is Part 2 of a two-part blog series. Read part 1: What is a TR‑FRET assay and how is it used in drug discovery? In a previous blog post, we covered the fundamental principles of Time-Resolved Fluorescence (TR) Förster Resonance Energy Transfer (TR-FRET), including how long-lived lanthanide donors like europium enable high-sensitivity, “mix-and-read” assays. Because TR-FRET provides a ratiometric, proximity-based […]

Triple ERC Success at the German Cancer Research Center

Triple ERC Success at the German Cancer Research Center

Three researchers at the German Cancer Research Center (DKFZ) have each been awarded a Starting Grant from the European Research Council (ERC) this year. Daniel Kirschenbaum, Lena Kutscher, and Michael Scherer impressed the ERC with their innovative research approaches to fundamental questions in cancer medicine. With the funding, they plan to investigate why certain brain […]

Cancer Cachexia: How a Tumor Protein Drives Wasting in the Body

Cancer Cachexia: How a Tumor Protein Drives Wasting in the Body

Researchers at Helmholtz Munich, the Heidelberg Faculty of Medicine at Heidelberg University, the German Center for Diabetes Research (DZD) and the Technical University of Munich (TUM) have identified a previously unknown mechanism that can drive cancer cachexia – a wasting process in the body that primarily affects muscle and fat tissue. A central role is […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp